Balansag, Rodelia B.
HRN: 08-69-08 Sex: FemalePatient Encounter
AMS Audit List
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/21/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
10/21/2023
10/28/2023
IV
600mg
Q8
Cutaneous Abscess
Checking Final Appropriateness
10/23/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/23/2023
10/29/2023
IV
2.25gm
Q8
Septicemia
Checking Final Appropriateness
10/23/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/23/2023
10/23/2023
IV
4.5gm
LD
Septicemia
Checking Final Appropriateness
10/31/2023
CLINDAMYCIN 300MG (CAP)
10/31/2023
11/07/2023
PO
2 Caps
Q8
Abscess
Checking Final Appropriateness
10/31/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/31/2023
11/07/2023
IV
4.5g
Q8
Abscess
Checking Final Appropriateness
11/01/2023
CLINDAMYCIN 300MG (CAP)
11/01/2023
11/07/2023
PO
600mg
Q8
Abscess, Cutaneous
Checking Final Appropriateness
11/05/2023
CLINDAMYCIN 300MG (CAP)
11/05/2023
11/08/2023
PO
600mg
Q8
Cutaneous Abscess Sec To Hornet Sting
Checking Final Appropriateness
11/05/2023
CO-AMOXICLAV 625MG (TAB)
11/07/2023
11/16/2023
PO
625mg
TID
Abscess, Supraorbital Area, Cutaneous
Checking Final Appropriateness